PAKT’s 40% operating margin trails regional BAT peers in India (61%) and Sri Lanka (76%), signalling long-term expansion potential. Pricing power remains a key lever, as historical unit price growth (15%) has consistently exceeded average inflation (10%).
The company trades at a price-to-earnings multiple of 12x and an attractive dividend yield of 8%. Despite volume declines, it has delivered a 5-year operating profit CAGR of 21% and warrants a re-rating toward branded food and pharma peers, which trade at 21x and 19x, respectively, given comparable margins and cash generation.
Investment Thesis
Crackdown on illicit sales to drive market share gains: Tax changes in the FY23 budget hit the formal sector hard, as a higher Federal Excise Duty (FED) made legal prices uncompetitive against illicit alternatives. PAKT’s volumes fell to a low of 28bn sticks in CY23 but have since stabilised at 29bn. Returning to its 10-year average of 38bn sticks implies a 31% upside in volume. Early signs of a successful government crackdown, including the seizure of 15bn sticks of illicit capacity (19% of the market), suggest a major tailwind, as the government is strongly incentivised to curb the sector to meet IMF fiscal commitments, especially considering illicit trade is responsible for an estimated PKR300bn in annual tax evasion. As the industry leader with a 36% share, PAKT is the primary beneficiary of this enforcement.
Room for further margin expansion: PAKT maintains robust economics through significant pricing power, with operating margins rising from 24% in CY15 to 40% over the trailing twelve months. Over the last decade, a 15% price CAGR outpaced 10% average inflation, sustaining profitability despite a 3.9% annual volume decline. We expect this volume headwind to become a tailwind following the government’s crackdown on illicit trade. Furthermore, PAKT’s margins still lag those of its South Asian peers in India and Sri Lanka (61% and 76%, respectively), suggesting further margin expansion is possible going forward.
Valuation remains attractive: With robust pricing power and a near-term tailwind from the illicit trade crackdown, PAKT offers a compelling investment case. This is bolstered by the success of its nicotine pouch, VELO, which has averaged 58% annual growth since CY21. Despite these fundamentals, PAKT trades at an attractive 12x PE and 8.3% dividend yield, representing a steep discount to the Branded Food (21x) and Pharma (19x) sectors.
Tentative Valuation
We estimate an expected annualized return rather than a target price, assuming entry at PKR1,510/sh. The stock offers an 8% dividend yield, and we conservatively assume 11% earnings growth in line with long-term nominal GDP (per IMF), despite the company’s 10-year NOPAT CAGR exceeding this level. We also factor in gradual re-rating to 20x over 5 years, adding c.11% annually. This implies a total expected annual return of c.30% compared to cost of equity of 18%.
Risks
(i) Any further increase in taxation on the formal tobacco sector, (ii) Government drive against curbing illicit tobacco trade loses steam
